SUTRO BIOPHARMA, INC.

STRO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $58.1M $190.3M $69.3M $47.3M $30.4M $206.2M $5.0M $125.3M
Accounts Receivable $4.0M $8.6M $36.1M $7.1M $12.5M $5.6M $6.3M $2.5M
Inventory
Total Current Assets $150.9M $343.3M $421.5M $353.2M $218.5M $378.2M $128.6M $209.9M
Property, Plant & Equipment $10.6M $18.2M $21.9M $24.6M $22.6M $12.9M $9.6M $10.9M
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $173.8M $387.2M $470.7M $406.9M $341.4M $394.1M $156.4M $223.1M
Liabilities
Accounts Payable $7.6M $10.5M $9.4M $4.8M $6.0M $5.5M $5.6M $3.1M
Total Current Liabilities $75.1M $131.9M $93.7M $66.5M $41.7M $29.6M $33.0M $36.4M
Long-Term Debt $0 $3.8M $15.7M $24.5M $8.9M $10.0M
Total Liabilities $306.3M $342.6M $321.1M $189.9M $88.8M $62.1M $58.6M $91.6M
Stockholders' Equity
Retained Earnings $-978.0M $-786.9M $-559.4M $-452.6M $-333.4M $-227.9M $-195.7M $-150.3M
Total Stockholders' Equity $-132.5M $44.6M $149.6M $217.0M $252.6M $332.0M $97.8M $131.5M
← Newer Page 1 of 2 Older →